MoonLake Immunotherapeutics (MLTX)
51.86
+2.04
(+4.09%)
USD |
NASDAQ |
Nov 21, 16:00
52.02
+0.16
(+0.30%)
After-Hours: 20:00
MoonLake Immunotherapeutics Shareholders Equity (Quarterly): 488.20M for Sept. 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 488.20M |
| June 30, 2024 | 520.66M |
| March 31, 2024 | 542.55M |
| December 31, 2023 | 495.68M |
| September 30, 2023 | 424.93M |
| June 30, 2023 | 489.80M |
| Date | Value |
|---|---|
| March 31, 2023 | 42.00M |
| December 31, 2022 | 48.90M |
| September 30, 2022 | 55.29M |
| June 30, 2022 | 63.51M |
| December 31, 2021 | -11.64M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-11.64M
Minimum
Dec 2021
542.55M
Maximum
Mar 2024
287.26M
Average
424.93M
Median
Sep 2023
Shareholders Equity (Quarterly) Benchmarks
| Novartis AG | 43.32B |
| AC Immune SA | 154.72M |
| CRISPR Therapeutics AG | 1.940B |
| Addex Therapeutics Ltd | 14.07M |
| NLS Pharmaceutics Ltd | -9.268M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 518.21M |
| Total Liabilities (Quarterly) | 22.71M |